

MSCopilot® As A Digital Tool To Collect Patients’ Insights In Health Economics Research In Multiple Sclerosis

Dulong C¹, Brochu T¹, Delgrange R¹, Bouaou K¹, Zinai S¹, Bouleau A², Schwerer CA², Švecová K³, Sá MJ⁴, Petropoulos A⁵, Aly S⁶, Labauge P⁷

¹Ad Scientiam, Paris, France; ²Asteres, Paris, France; ³Independent HEOR Consultant, Zurich, Switzerland
⁴Centro Hospitalar Universitário de São João and Universidade Fernando Pessoa, Porto, Portugal
⁵Novartis Hellas, Metamorphosis, Athens, A, Greece; ⁶Novartis Pharma, Basel, Switzerland
⁷Département de Neurologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France

What Is MSCopilot® ?

MSCopilot® is a CE-marked software medical device used by **multiple sclerosis (MS) patients**, providing clinically validated digital biomarkers in four dimensions¹. (Figure 1)

Figure 1. Dimensions monitored by MSCopilot®



208 Participants, 142 Questions

A patient-based questionnaire consisting of 142 questions was administered to the 208 enrolled participants of the study via **MSCopilot® and email**. The questionnaire collected data on patients’ and disease characteristics, productivity losses, employment status, caregivers and the number of consultations with healthcare professionals.

Questionnaire :

Did one of your relatives have to reduce their working time to care for you ?

Have you ever gave up on purchasing an equipment because of a lack of means ?

Since your diagnosis, have you ever bought or rented an adapted vehicle ?

Have you ever needed to take an extended sick leave because of your disease ?

Also


profiling questions such as the **age** when diagnosed, annual **income**, **professional situation** ...

The statistical representativeness of MS participants included in the survey was compared with the **overall French MS population**. The representativeness of the sample was tested using the Exact binomial test or the χ^2 conformity test.

Categorical variables were reported as counts and percentages, while continuous measures were summarised as means and standard deviations (SD).

Results


Overall, 206 of the 208 MS participants were included in this study.



Among these, **60.7% were recruited via MSCopilot®** users, while 39.3% were recruited through email.

A **high response rate** to the survey was observed (11.9%).

Figure 2. Key characteristics of the survey patients and the French MS population



Compared to the French MS population, the sample was statistically representative in its sex distribution (**78.6% vs 73.0% female**, confidence interval = 72.4% - 84.0%, Exact binomial test), **younger (42.3 vs 51.0 years**, $p < 0.0001$, χ^2 conformity test) and composed of **70.9% of RMS** (confidence interval = 64.2% - 77.0%) **and 25.2% PMS** (confidence interval = 19.5% - 31.7%) (Figure 2.)



95% of participants reported their willingness to **participate in similar studies** in the future.

Conclusions

The effective response rate observed in this study and the representativeness to the overall MS population in France suggest that **MSCopilot® is a valuable and relevant digital tool for collecting patients’ insights in MS**.

References

1- Maillart E, Labauge P, Cohen M, et al. MSCopilot, a new multiple sclerosis self-assessment digital solution: Results of a comparative study versus standard tests. Eur J Neurol 2020; 27: 429–436.
2- Detournay B, Debouverie M, Pereira O, et al. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord 2019; 36: 101396.

Disclosures The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A Bouleau and CA Schwerer are employees of Asterès. C Dulong, R Delgrange, K Bouaou, T Brochu, S Zinai are employees of Ad Scientiam. K Švecová is an independent HEOR Consultant and has no conflict of interest. Prof. Sá has received honoraria from Amgen, Bayer Healthcare, Biogen, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Prof. Labauge has received honoraria and grants from Novartis, Sanofi Genzyme, Merck and Roche. A Petropoulos and S Aly are full-time employees of Novartis.

Funding This study was supported by Novartis Pharma AG, Basel, Switzerland.